Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BREC Study: BRCA1 expression customization in advanced non-small cell lung cancer
2007-004278-20Phase 3Terminated
- Sponsor
- Fundación GECP
- Start
- Nov 2007
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of cisplatin, gemcitabine and docetaxel in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Fundación GECP. Primary endpoint: Median time to progression. Started Nov 2007; status: terminated.
02
Drugs
cisplatingemcitabinedocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2007-004278-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004278-20.